Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Escalating Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous OPL-CCL2-LPM in Patients With IgA Nephropathy

NCT00856674 is registered in ClinicalTrials.gov with Osprey Pharmaceuticals USA, Inc. as lead sponsor.

NCT NCT00856674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00856674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Escalating Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous OPL-CCL2-LPM in Patients With IgA Nephropathy
Lead sponsor
Osprey Pharmaceuticals USA, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
March 31, 2009
Completion date
June 30, 2010
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy, proteinuria